Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.31 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.31 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | DRD1 | P21728 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2139483 | 0.83 | LMNA (0.30) | LMNACHRM2ADRA2ACYP2D6TSHR | |
| SCHEMBL25456111 | 0.79 | NEK2 (0.35) | — | |
| SCHEMBL2142153 | 0.73 | SLC6A2 (0.35) | LMNACHRM2ADRA2ACYP2D6TSHR | |
| SCHEMBL20504377 | 0.73 | TRPM8 (0.30) | — | |
| SCHEMBL18785209 | 0.73 | HSD11B1 (0.33) | — | |
| SCHEMBL23015962 | 0.73 | CRBN (0.32) | — | |
| SCHEMBL2635619 | 0.73 | CRBN (0.38) | — | |
| Trifluoroacetic Acid SCHEMBL17318813 | 0.72 | — | — | |
| SCHEMBL17317198 | 0.70 | LMNA (0.69) | LMNACHRM2ADRA2ACYP2D6TSHR | |
| SCHEMBL31580621 | 0.70 | GAA (0.31) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11649248-B2 | Oxadiazaspiro compounds for the treatment of drug abuse and addiction | ESTEVE PHARMACEUTICALS, S.A. (ES) | 2023-05-16 | — | — | US | disclosed |
| US-20210115062-A1 | OXADIAZASPIRO COMPOUNDS FOR THE TREATMENT OF DRUG ABUSE AND ADDICTION | ESTEVE PHARMACEUTICALS SA (ES) | 2021-04-22 | — | — | US | disclosed |
| US-10927128-B2 | Oxadiazaspiro compounds for the treatment of drug abuse and addiction | ESTEVE PHARMACEUTICALS. S.A. (ES) | 2021-02-23 | — | — | US | disclosed |
| US-20180327422-A1 | OXADIAZASPIRO COMPOUNDS FOR THE TREATMENT OF DRUG ABUSE AND ADDICTION | ESTEVE PHARMACEUTICALS, S.A. (ES) | 2018-11-15 | — | — | US | disclosed |
| EP-3377500-A1 | OXADIAZASPIRO COMPOUNDS FOR THE TREATMENT OF DRUG ABUSE AND ADDICTION | ESTEVE PHARMACEUTICALS, S.A. (ES) | 2018-09-26 | — | — | EP | disclosed |
| EP-3149006-A1 | ALKYL DERIVATIVES OF 1-OXA-4,9-DIAZASPIRO UNDECANE COMPOUNDS HAVING MULTIMODAL ACTIVITY AGAINST PAIN | Laboratorios Del. Dr. Esteve, S.A. (ES) | 2017-04-05 | — | — | EP | disclosed |
| EP-3149007-A1 | ALKYL AND ARYL DERIVATIVES OF 1-OXA-4,9-DIAZASPIRO UNDECANE COMPOUNDS HAVING MULTIMODAL ACTIVITY AGAINST PAIN | Laboratorios Del. Dr. Esteve, S.A. (ES) | 2017-04-05 | — | — | EP | disclosed |
| EP-3149005-A1 | AMIDE DERIVATIVES OF 1-OXA-4,9-DIAZASPIRO UNDECANE COMPOUNDS HAVING MULTIMODAL ACTIVITY AGAINST PAIN | Laboratorios Del. Dr. Esteve, S.A. (ES) | 2017-04-05 | — | — | EP | disclosed |
| WO-2015185209-A1 | ALKYL DERIVATIVES OF 1-OXA-4,9-DIAZASPIRO UNDECANE COMPOUNDS HAVING MULTIMODAL ACTIVITY AGAINST PAIN | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2015-12-10 | — | — | WO | disclosed |
| WO-2015185207-A1 | ALKYL AND ARYL DERIVATIVES OF 1-OXA-4,9-DIAZASPIRO UNDECANE COMPOUNDS HAVING MULTIMODAL ACTIVITY AGAINST PAIN | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2015-12-10 | — | — | WO | disclosed |
| WO-2015185208-A1 | AMIDE DERIVATIVES OF 1-OXA-4,9-DIAZASPIRO UNDECANE COMPOUNDS HAVING MULTIMODAL ACTIVITY AGAINST PAIN | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2015-12-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180327422-A1 | OXADIAZASPIRO COMPOUNDS FOR THE TREATMENT OF DRUG ABUSE AND ADDICTION | OPRD1, OPRM1, OPRK1 | LMNA 4741/4885CHRM2 819/4885ADRA2A 35/4885 |
| US-11649248-B2 | Oxadiazaspiro compounds for the treatment of drug abuse and addiction | OPRD1, OPRM1, OPRK1 | LMNA 4741/4885CHRM2 819/4885ADRA2A 35/4885 |
| US-10927128-B2 | Oxadiazaspiro compounds for the treatment of drug abuse and addiction | OPRD1, OPRM1, OPRK1 | LMNA 4741/4885CHRM2 819/4885ADRA2A 35/4885 |
| US-20210115062-A1 | OXADIAZASPIRO COMPOUNDS FOR THE TREATMENT OF DRUG ABUSE AND ADDICTION | OPRD1, OPRM1, OPRK1 | LMNA 4809/4885CHRM2 949/4885ADRA2A 45/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.